<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03750201</url>
  </required_header>
  <id_info>
    <org_study_id>GLAUrious-2017-01</org_study_id>
    <nct_id>NCT03750201</nct_id>
  </id_info>
  <brief_title>A Study to Assess an Automated Laser Device for Direct Selective Laser Trabeculoplasty</brief_title>
  <acronym>GLAUrious</acronym>
  <official_title>Direct Selective Laser Trabeculoplasty (DSLT) In Open Angle Glaucoma (POAG): A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Belkin Laser Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Commission</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universita degli Studi di Genova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Queen's University, Belfast</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Moorfields Eye Hospital NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Belkin Laser Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glaucoma is an eye disease that results in damage to the optic nerve that progresses over&#xD;
      time. One of the main risk factors in glaucoma is an increase in intraocular pressure, caused&#xD;
      by a build-up of fluid in the eye. Glaucoma can result in blindness if left untreated and as&#xD;
      such it is extremely important to diagnose and treat the condition.&#xD;
&#xD;
      Selective Laser Trabeculoplasty (SLT) is a laser treatment that facilitates the outflow of&#xD;
      fluid from inside the eye. This has the potential of reducing the intraocular pressure within&#xD;
      the eye (the main way in which this disease is treated since there is no cure) and may assist&#xD;
      in helping to control the progression of this disease.&#xD;
&#xD;
      SLT (standard treatment) is a technique routinely carried out by glaucoma specialists. It is&#xD;
      conducted using a special type of lens (goniolens) that gently sits on the front surface of&#xD;
      the eye. The procedure takes approximately 5 minutes in duration.&#xD;
&#xD;
      This new treatment, Direct Selective Laser Trabeculoplasty (DSLT) is performed directly,&#xD;
      without there being any need to use a goniolens which sits on the eye, and it is a shorter&#xD;
      and simpler technique to conduct when compared to the standard SLT technique.&#xD;
&#xD;
      The purpose of this study is to assess the hypothesis that the treatment by new automated&#xD;
      device for DSLT is not worse in comparison with the standard SLT and determine that it is&#xD;
      effective in reducing intraocular pressure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Glaucoma can result in blindness if left untreated and as such it is extremely important to&#xD;
      diagnose and treat the condition.&#xD;
&#xD;
      Usually doctors treat the first symptoms of glaucoma or ocular hypertension by prescribing&#xD;
      eye drops. Unfortunately, there can be side effects associated with the use of these eye&#xD;
      drops and there are reports of non-compliance due to difficulties in inserting these drops,&#xD;
      all of which can impact on how effective this treatment regimen is.&#xD;
&#xD;
      The purpose of this study is to assess how well the new automated DSLT device for laser&#xD;
      treatment of glaucoma or ocular hypertension works in comparison with the standard SLT and&#xD;
      determine that it is as effective in reducing intraocular pressure.&#xD;
&#xD;
      DSLT or SLT will be performed in the study eye according to the randomization assignment.&#xD;
      Eligible patients who sign the informed consent will be enrolled at each of the study sites,&#xD;
      and undergo a washout (in the case of being medicated). After washout there will be a&#xD;
      baseline visit, where continued eligibility is confirmed. Following confirmation of continued&#xD;
      eligibility, 50% of patients being randomized to each treatment group. Randomization will be&#xD;
      to a pre-determined randomization list.&#xD;
&#xD;
      The un-masked investigator(s) will open the envelope corresponding to the subject ID and&#xD;
      administer the treatment as indicated by the randomization envelope. The masked&#xD;
      ophthalmologist(s), who will perform the follow up, will be masked as to the nature of the&#xD;
      treatment the patient underwent.&#xD;
&#xD;
      Only one eye per participant will be included in the study and they will be treated using&#xD;
      either DSLT or SLT as per the randomized treatment allocation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2018</start_date>
  <completion_date type="Anticipated">November 2022</completion_date>
  <primary_completion_date type="Anticipated">April 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>Intra-ocular pressure (IOP) measurements by masked investigator or masked technique (masked reading).</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>The difference between the two treatment groups between the mean baseline IOP and the mean IOP after the treatment</measure>
    <time_frame>6 months</time_frame>
    <description>The mean baseline IOP (washed out for medicated patients) will be compared to the mean (washed out for medicated patients) IOP after the treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of medications as compare to screening visit</measure>
    <time_frame>6 months</time_frame>
    <description>Number of medications at 6 months as compared to screening/Visit 1 (before treatment) and compared between groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with at least 20% reduction in IOP from baseline</measure>
    <time_frame>6 months</time_frame>
    <description>Proportion of subjects with at least 20% reduction in IOP at 6 months compared to baseline without surgical intervention</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>Rates of Ocular Adverse events (AEs) in each treatment group at or prior to the 12 months visit</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">192</enrollment>
  <condition>Open Angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Direct Selective Trabeculoplasty</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment by the investigational device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selective Trabeculoplasty</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment by the comparator device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Direct Selective Trabeculoplasty</intervention_name>
    <description>Laser surgery by automated direct automated SLT device to lower intraocular pressure</description>
    <arm_group_label>Direct Selective Trabeculoplasty</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Selective Trabeculoplasty</intervention_name>
    <description>Laser surgery by standard SLT device to lower intraocular pressure</description>
    <arm_group_label>Selective Trabeculoplasty</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 40 years or older, with visual acuity &gt; 6/60 in both eyes&#xD;
&#xD;
          2. Open angle glaucoma including exfoliative or pigmentary glaucoma or ocular&#xD;
             hypertension&#xD;
&#xD;
          3. IOP ≥ 22mmHg to ≤35mmHg (after washout of any IOP-lowering medications)&#xD;
&#xD;
          4. Gonioscopically visible scleral spur for 360 degrees without indentation&#xD;
&#xD;
          5. Ability to visualize the peri-limbal sclera for 360 degrees (using a lid speculum)&#xD;
&#xD;
          6. Willing and able to participate in the 12-month study, to comply with the study&#xD;
             procedures and to adhere to the follow-up schedule&#xD;
&#xD;
          7. Participant capable of giving informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindications to conventional laser trabeculoplasty (e.g. corneal abnormalities,&#xD;
             etc.)&#xD;
&#xD;
          2. Angle Closure Glaucoma&#xD;
&#xD;
          3. Congenital or developmental glaucoma&#xD;
&#xD;
          4. Secondary glaucoma except exfoliative or pigmentary glaucoma&#xD;
&#xD;
          5. Presence of any Peripheral Anterior Synechiae (PAS) in the study eye&#xD;
&#xD;
          6. Inability to conduct a reliable visual field (defined as fixation losses, false&#xD;
             positives or false negatives greater than 33%)&#xD;
&#xD;
          7. Any of the following visual field findings using the Humphrey visual field analyzer&#xD;
             the SITA-standard 24-2 program:&#xD;
&#xD;
               1. A visual field MD of worse than -12dB&#xD;
&#xD;
               2. Greater than or equal to 75% of points depressed below the 5% level and greater&#xD;
                  than or equal to 50% of points depressed below the 1% level on the PD plot&#xD;
&#xD;
               3. At least 50% of points (i.e 2 or more) within the central 5 degrees with a&#xD;
                  sensitivity ≤0dB on the decibel plot&#xD;
&#xD;
               4. Points within the central 5 degrees of fixation with a sensitivity &lt;15 dB in both&#xD;
                  hemifields on the decibel plot&#xD;
&#xD;
          8. A visual field MD of worse than -12dB in the fellow eye&#xD;
&#xD;
          9. Cup:Disc Ratio of more than 0.8&#xD;
&#xD;
         10. More than three hypotensive mediations required&#xD;
&#xD;
         11. Prior incisional or laser glaucoma surgery (including previous SLT) in the study eye&#xD;
&#xD;
         12. Prior corneal refractive surgery&#xD;
&#xD;
         13. Complicated cataract surgery ≤ 6 months prior to enrollment&#xD;
&#xD;
         14. Presence of visually significant cataract in the opinion of the investigator&#xD;
&#xD;
         15. Clinically significant disease in either eye as determined by the Investigator&#xD;
&#xD;
         16. Clinically significant amblyopia in either eye&#xD;
&#xD;
         17. Dense pigmentation or haemorrhage in the peri-limbal conjunctiva or anterior sclera&#xD;
&#xD;
         18. Women who are pregnant or may become pregnant during the study&#xD;
&#xD;
         19. In the opinion of the investigator the participant might require other ocular surgery&#xD;
             within the 12-month follow-up period, unless for further reduction of their IOP&#xD;
&#xD;
         20. Concurrent treatment with topical, nasal, inhaled or systemic steroids&#xD;
&#xD;
         21. Uncontrolled systemic disease that could impact the ability of the participant to&#xD;
             attend follow up visits as per the discretion of the investigator&#xD;
&#xD;
         22. Participation in another clinical study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nathan Congdon, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queens University Belfast</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yoram Solberg, MD PhD</last_name>
    <phone>+972542346137</phone>
    <email>yoram@belkin-laser.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Soroka Medical Center</name>
      <address>
        <city>Be'er Sheva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mor Portnikov</last_name>
      <email>MorPo@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Assaff Kratz, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rambam Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meital Abecassis</last_name>
      <email>m_abecassis@rambam.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Eytan Blumenthal, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Drozdov</last_name>
      <email>Elizabethd@wmc.gov.il</email>
    </contact>
    <investigator>
      <last_name>Maya Kalev - Lindoy, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Shaare Zedek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hila Givoni</last_name>
      <email>hilag@szmc.org.il</email>
    </contact>
    <investigator>
      <last_name>Zohar Bracha, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rabin Medical Center</name>
      <address>
        <city>Petah-Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vivi Dagan</last_name>
      <phone>03-9377199</phone>
      <email>eyeclinic@clalit.org.il</email>
    </contact>
    <investigator>
      <last_name>Noa Geffen, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universita degli Studi di Genova</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maura Cavo</last_name>
      <phone>+3901035338290</phone>
      <email>mauracavo@alice.it</email>
    </contact>
    <contact_backup>
      <last_name>Luca Bagnasco, PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Carlo E Traverso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queens University Belfast</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucia Dalton</last_name>
      <phone>07768 858583</phone>
      <email>L.Dalton@qub.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Augusto Azuara-Blanco, PhD,FRCOphth</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hospital</name>
      <address>
        <city>London</city>
        <zip>EC1V 2PD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Reem Deib</last_name>
      <phone>0207 566 2821</phone>
      <email>reem.deib@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Gus Gazzard, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>Italy</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 19, 2018</study_first_submitted>
  <study_first_submitted_qc>November 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 21, 2018</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

